Patents Assigned to NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD.
  • Anti-pancreatic cancer monoclonal antibody and use thereof
    Patent number: 10444237
    Abstract: A hybridoma cell line NM002-1 secreting an anti-human pancreatic cancer monoclonal antibody and deposited under CCTCC Accession NO: C201173. Also, an anti-human pancreatic cancer monoclonal antibody NJ002-1 secreted by the hybridoma cell line NM002-1 and use thereof.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: October 15, 2019
    Assignee: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD.
    Inventors: Yue Pan, Shiyang Pan, Jian Xu
  • ANTI-PANCREATIC CANCER MONOCLONAL ANTIBODY AND USE THEREOF
    Publication number: 20180224457
    Abstract: A hybridoma cell line NM002-1 secreting an anti-human pancreatic cancer monoclonal antibody and deposited under CCTCC Accession NO: C201173. Also, an anti-human pancreatic cancer monoclonal antibody NJ002-1 secreted by the hybridoma cell line NM002-1 and use thereof.
    Type: Application
    Filed: July 26, 2016
    Publication date: August 9, 2018
    Applicant: NANJING MARKERLINE BIOMEDICAL TECHNOLOGY CO., LTD.
    Inventors: Yue PAN, Shiyang PAN, Jian XU